Maxim Pharmaceuticals Reports Fiscal 2004 Financial Results
December 13, 2004 03:12 ET
|
Maxim Pharmaceuticals
STOCKHOLM, Sweden and SAN DIEGO, Dec. 13, 2004 (PRIMEZONE) -- Maxim Pharmaceuticals, Inc. (Nasdaq:MAXM) (SSE:MAXM) today reported financial results for the fourth quarter and the year ended September...
Myriad Genetics Files IND For Drug Candidate From Compound Family Licensed From Maxim Pharmaceuiticals
December 09, 2004 07:15 ET
|
Maxim Pharmaceuticals
STOCKHOLM, Sweden and SAN DIEGO, Dec. 9, 2004 (PRIMEZONE) -- Maxim Pharmaceuticals, Inc. (Nasdaq:MAXM) (SSE:MAXM) today reported that Myriad Genetics, Inc., filed an Investigational New Drug (IND)...
Maxim Pharmaceuticals Reports Data from its Phase 3 Trial of Ceplene in Acute Myeloid Leukemia Patients at American Society of Hematology Annual Meeting
December 06, 2004 14:54 ET
|
Maxim Pharmaceuticals
SAN DIEGO, Dec. 6, 2004 (PRIMEZONE) -- Maxim Pharmaceuticals (Nasdaq:MAXM) (SSE:MAXM) announced today additional data from its randomized and controlled Phase 3 trial (MP-MA-0201) investigating...
Maxim's Senior Director of Regulatory Affairs and Drug Safety Resigns
December 06, 2004 14:29 ET
|
Maxim Pharmaceuticals
SAN DIEGO, Dec. 6, 2004 (PRIMEZONE) -- Maxim Pharmaceuticals (Nasdaq:MAXM) (SSE:MAXM) announced today that Richard Lowenthal, Senior Director of Regulatory Affairs and Drug Safety at Maxim, has...
Maxim Pharmaceuticals to Host Conference Call
December 03, 2004 00:58 ET
|
Maxim Pharmaceuticals
STOCKHOLM, Sweden, and SAN DIEGO, Dec. 3, 2004 (PRIMEZONE) -- Maxim Pharmaceuticals (Nasdaq:MAXM) (SSE:MAXM) today announced it will hold a conference call on Tuesday, December 7, 2004 at 10:00 a.m....
Maxim Pharmaceuticals Announces Publication of Two Manuscripts Describing Pre-Clinical Anticancer Activity in Novel Class of Microtubule Inhibitors
December 01, 2004 14:21 ET
|
Maxim Pharmaceuticals
SAN DIEGO, Dec. 1, 2004 (PRIMEZONE) -- Maxim Pharmaceuticals (Nasdaq:MAXM) (SSE:MAXM) announced today the publication of two manuscripts in the Journal of Molecular Cancer Therapeutics (Mol Cancer...
Maxim Pharmaceuticals to Close Treatment Protocol and Withdraw NDA for Advanced Malignant Melanoma
November 01, 2004 03:08 ET
|
Maxim Pharmaceuticals
STOCKHOLM, Sweden and SAN DIEGO, Nov. 1, 2004 (PRIMEZONE) -- Maxim Pharmaceuticals (Nasdaq:MAXM) (SSE:MAXM) announced today that based upon the negative outcome of it's confirmatory Phase 3 clinical...
Maxim Pharmaceuticals to Present at Rodman & Renshaw Conference
October 22, 2004 03:10 ET
|
Maxim Pharmaceuticals
STOCKHOLM, Sweden, Oct. 22, 2004 (PRIMEZONE) -- Maxim Pharmaceuticals (Nasdaq:MAXM) (SSE:MAXM) today announced that it will present at the Rodman & Renshaw Techvest 6th Annual Healthcare Conference...
Maxim Pharmaceuticals Appoints John F. Bedard To Board Of Directors
October 05, 2004 03:04 ET
|
Maxim Pharmaceuticals
SAN DIEGO and STOCKHOLM, Sweden, Oct. 5, 2004 (PRIMEZONE) -- Maxim Pharmaceuticals (Nasdaq:MAXM) (SSE:MAXM) announced today that John F. Bedard, 55, was appointed to the Company's board of directors....
Maxim Pharmaceuticals Presents Preclinical Results of Novel Cancer Compound Discovered by Its Research Team at The AACR-EORTC
October 01, 2004 02:11 ET
|
Maxim Pharmaceuticals
STOCKHOLM, Sweden and SAN DIEGO, Oct. 1, 2004 (PRIMEZONE) -- Maxim Pharmaceuticals (Nasdaq:MAXM) (SSE:MAXM) reported earlier this week at the AACR-EORTC-NCI International Conference "Molecular...